Literature DB >> 33609799

Neuropsychiatric involvement in systemic lupus erythematosus: A review.

Irene Carrión-Barberà1, Tarek Carlos Salman-Monte2, F Vílchez-Oya3, Jordi Monfort4.   

Abstract

The neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is a challenge for clinicians, both at a diagnostic and therapeutic level. Although in 1999 the American College of Rheumatology (ACR) proposed a set of definitions for 19 NPSLE syndromes, with the intention of homogenizing the terminology for research purposes and clinical practice, the prevalence of NPSLE varies widely according to different series and is estimated to be between 37 and 95%. This is due to multiple factors such as the unalike definitions used, the diverse design of the studies, type of population, race, type and severity of symptoms, and follow-up of the different cohorts of patients with SLE. In recent years, some authors have tried excluding minor neuropsychiatric manifestations in order to try to reduce this wide variation in the prevalence of NPSLE since they are very prevalent in the general population; others authors have developed various models for the attribution of neuropsychiatric events to SLE that can assist clinicians in this diagnostic process, and finally, some authors developed and validated in 2014 a new algorithm based on the definitions of the ACR that includes the evaluation of the patient's lupus activity together with imaging techniques and the analysis of cerebrospinal fluid (CSF), with the aim of trying to differentiate the true neuropsychiatric manifestations attributable to SLE. In 2010, the European League Against Rheumatism (EULAR) developed recommendations for the management of NPSLE. We found abundant literature published later where, in addition to the recommendations for the management of the 19 NPSLE syndromes defined by the ACR, additional recommendations are given for other neurological and/or psychiatric syndromes, conditions, and complications that have been associated to SLE in recent years. We review below the diagnostic and therapeutic management of the different entities.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Neuropsychiatric involvement; Neuropsychiatric lupus; SLE activity; Systemic lupus erythematosus

Mesh:

Year:  2021        PMID: 33609799     DOI: 10.1016/j.autrev.2021.102780

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

Review 1.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

2.  MiR-301a-3p Advances IRAK1-Mediated Differentiation of Th17 Cells to Promote the Progression of Systemic Lupus Erythematosus via Targeting PELI1.

Authors:  Shuaihantian Luo; Ruifang Wu; Qianwen Li; Guiying Zhang
Journal:  J Healthc Eng       Date:  2021-12-11       Impact factor: 2.682

3.  Case Report: Rapid Progression of Cognitive Dysfunction as an Initial Feature of Systemic Lupus Erythematosus With Leukoencephalopathy: A Case Report and Literature Review.

Authors:  Yukun Feng; Teng Yu; Qin Xiao; Xiaodong Yang
Journal:  Front Neurol       Date:  2022-07-11       Impact factor: 4.086

Review 4.  Motor neuron disease in a patient with overlap syndrome (rheumatoid arthritis; systemic lupus erythematosus, Sjogren's syndrome).

Authors:  Ebru Atalar; Fatma Gül Yurdakul; Kevser Gök; Tuba Güler; Şükran Erten; Evren Yaşar; Hatice Bodur
Journal:  Rheumatol Int       Date:  2022-09-18       Impact factor: 3.580

5.  Increased expression of cyclooxygenase-2 in synovium tissues and synovial fluid from patients with knee osteoarthritis is associated with downregulated microRNA-758-3p expression.

Authors:  Zhen Liu; Jing Sun; Tingting Liang; Xiaonan Huang
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.